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a  b  s  t  r  a  c  t
Background:  Respiratory  syncytial  virus  (RSV)  causes  signiﬁcant  illness  in  older  adults  resulting  in sub-
stantial  health  and economic  impact.  A  successful  vaccine  would  reduce  morbidity  in this  growing
segment  of  the population.
Methods:  In this  double-blind  phase  1 study,  subjects  60 years  of  age  and  older  were  enrolled  by  cohort  and
randomized  to receive  vaccines  containing  escalating  doses  (20,  50,  or  80 g) of soluble  RSV  fusion  protein
(sF)  alone  or  adjuvanted  with  2.5 g of glucopyranosyl  lipid  A, a toll-like  receptor-4  agonist,  in  2%  stable
emulsion  (GLA-SE).  Each cohort  included  20 vaccine  and  4 placebo  recipients.  Immune  responses  were
evaluated  using  assays  for RSV microneutralizing,  anti-F  IgG,  and  palivizumab  competitive  antibodies
and  for  F-speciﬁc  interferon  (IFN)-  enzyme-linked  immunospot  (ELISPOT)  responses.
Results:  The  inclusion  of adjuvant  increased  local  reactogenicity,  with  the majority  of subjects who
received  sF  and  adjuvant  reporting  low-grade  injection  site pain  or tenderness.  At  all  doses,  the  safety
proﬁle  was acceptable  for further  development.  Immune  responses  were  antigen  dose-dependent,  and
the inclusion  of adjuvant  increased  both  humoral  and  cellular  immune  responses,  with  responses  statis-
tically higher  than  for placebo  recipients  in  all 4 assays.  At  the  highest  dosage  level with  adjuvant,  half  of
the  subjects  had  a  ≥3-fold  rise  from  day  0  in  RSV  neutralizing  antibody  titers, and all  had  a ≥3-fold  rise
in  antibody  levels  by anti-F  IgG  and  palivizumab  competitive  antibody  assays  on day  29.  For  the  day  8
IFN  ELISPOT  assay,  74%  of  subjects  in  the highest  dosing  cohort  had  a ≥3-fold  rise from  baseline.
Conclusions:  The  safety  and immunogenicity  results  from  this  study  support  inclusion  of the  GLA-SE
adjuvant  in  this  RSV  vaccine  for older  adults  and  also  support  assessment  of the efﬁcacy  of the  vaccine
in  a  larger  clinical  trial.  Clinicaltrials.gov  NCT02115815.
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1. Introduction
Respiratory syncytial virus (RSV) is gaining recognition as an
important cause of disease in older adults [1–3]. RSV-induced ill-
ness is clinically indistinguishable from inﬂuenza and has a peak
incidence in winter in temperate zones [4,5]. Physicians do not
routinely test for RSV in adults, as there is no speciﬁc treatment;
however, RSV is a recognized cause of adult illness worldwide
[6–8]. Estimates suggest that the current burden of RSV in older
adults is comparable to, or greater than, that of inﬂuenza [9]. RSV
reinfection is common, presumably because of a short duration of
immunity after natural infection [10,11]. An adult vaccine would
most likely require annual administration, which could occur at
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he time of inﬂuenza vaccination. An effective RSV vaccine for older
dults would decrease RSV-related morbidity and be cost-effective
12,13].
We report the results of a phase 1 study of investigational RSV
accines as the initial step in developing a vaccine for the preven-
ion of RSV disease in adults ≥60 years of age. This population was
elected because RSV disease severity increases with age, likely due
o the increase in comorbid conditions as well as to immunose-
escence [14–16]. Given the ubiquity of RSV infection, all adults
re seropositive. Older adults have antibody levels similar to those
f younger adults, and higher antibody titers are associated with
ecreased risk of RSV disease in older adults [16,17]. However, cell-
ediated immune responses to RSV are deﬁcient in older adults
ompared with younger adults [17]. Thus, the use of an adjuvant
elected to boost cellular as well as humoral immunity was assessed
n this study.
The RSV vaccines tested in this study contained soluble RSV
usion protein (sF) in the postfusion form. F protein is essential for
roductive infection and is the only highly conserved RSV protein
apable of eliciting substantial neutralizing antibody titers [18].
SV F is a clinically validated target, as demonstrated by the efﬁ-
acy of palivizumab, a monoclonal antibody that binds to both the
re- and postfusion forms of F and decreases severe RSV disease
n high-risk infants [19]. Unlike inﬂuenza vaccines, which require
nnual reformulation based upon worldwide circulating inﬂuenza
trains, an RSV F vaccine is expected to maintain annual efﬁcacy
ithout requiring reformulation.
The effect of the adjuvant glucopyranosyl lipid A (GLA), a syn-
hetic analog of monophosphoryl lipid A (a toll-like receptor-4
TLR-4] agonist) formulated in a squalene-based oil-in-water sta-
le emulsion (SE), on the immunogenicity of the investigational
accines was evaluated in this study. GLA stimulates immune
esponses conducive to a T-helper type 1 vaccine response [20].
n animal models, a vaccine containing RSV sF and adjuvant GLA-
E elicited high neutralizing antibody titers and a T-helper type
-biased immune response with strong F-speciﬁc interferon (IFN)-
 T-cell responses, a response proﬁle that we hypothesize will be
ptimal in older adults [21,22].
We present data from our ﬁrst-time-in-human study of an RSV
F vaccine assessed in the presence and absence of adjuvant: 2.5 g
f GLA in 2% SE (GLA-SE). The primary objective was to assess the
afety and tolerability of a single ascending dose of RSV sF alone
nd in the presence of GLA-SE in adults ≥60 years of age who
ere healthy or who had stable, chronic underlying medical con-
itions. RSV-speciﬁc humoral and cellular immune responses pre-
nd postvaccination were assessed.
. Materials and methods
.1. Ethics statement
The study (clinicaltrials.gov NCT02115815) was carried out in
ccordance with the Declaration of Helsinki and good clinical
ractice guidelines. The study protocol and amendments, along
ith the subject informed consent document, were approved by an
nstitutional review board. All subjects provided written informed
onsent prior to any study procedures.
.2. Study design
This was a double-blind, randomized, placebo-controlled study.
ubjects were randomized at three sites in the United States
etween April and June 2014. Cohorts of 24 subjects were enrolled
onsecutively; allocation to cohort was unblinded. The 6 cohorts
onsisted of 3 dosage levels of RSV sF (20, 50, and 80 g) and those (2016) 2847–2854
same doses of RSV sF with GLA-SE. Within a cohort, subjects were
randomly allocated by an internet-based interactive response sys-
tem in a 5:1 ratio (20 active, 4 saline placebo). In a preplanned
interim analysis, the study was partially unblinded after subjects
had completed 90 days of safety follow-up. Site staff and subjects
remained blinded through the end of the study (day 361).
2.3. Subject selection
Subjects were required to be ≥ 60 years of age and not institu-
tionalized or homebound, to weigh ≥110 lbs (50 kg), and to have
normal hemoglobin concentrations. Major exclusions included an
unstable medical condition or recent change in therapy, receipt of
products that could include exogenous antibodies, clinically sig-
niﬁcant abnormalities in screening tests, viral hepatitis, history
of or current autoimmune disorder other than hypothyroidism,
immunosuppression, body mass index ≥ 40 kg/m2, or medications
or conditions that could cause injection site bleeding.
2.4. Vaccine preparation and administration
RSV sF (in the post-fusion conformation [18]), which differs from
the pre-fusion conformation described by McLellan et al. [23] was
expressed in a Chinese hamster ovary cell line. GLA-SE was pro-
vided by and licensed from Immune Design Corporation pursuant
to an existing agreement (Seattle, WA). Dose preparation occurred
on-site with administration within 3 h of mixing and 30 min  of
syringe ﬁlling. The barrel was  covered to blind administration. A
single 0.5 mL  intramuscular dose was  administered into the del-
toid muscle with needle gauge and length selected for gender and
weight [24].
2.5. Safety assessments
Study visits occurred on dosing day 1 and (approximately) post-
dose days 8, 29, 61, 91, 181, 271, and 361. Safety data assessed
included speciﬁed solicited symptoms collected by diary card dur-
ing days 1–7; adverse events (AEs) collected days 1–28; and serious
AEs, new onset chronic diseases, and AEs of special interest includ-
ing autoimmune events, collected days 1–361. An independent,
external safety monitoring committee reviewed 7 days of safety
data for cohort escalation. Interim follow-up by telephone occurred
at least monthly. Toxicity grading was  in general accordance with
a standard toxicity table [25].
2.6. Immunogenicity assessments
Immunogenicity data collected included RSV microneutralizing
(MN), anti-F IgG (F IgG), and palivizumab competitive antibodies
(PCA) and F-speciﬁc IFN- enzyme-linked immunospot (ELISPOT)
responses. RSV-neutralizing antibody titers in heat-inactivated
sera were measured using a green ﬂuorescent protein-tagged
RSV A2 MN assay (without complement) as previously described
[26]. Anti-F IgG antibodies were determined using a multiplex F,
Ga, Gb (RSV A and B subtypes of the G protein), and N-speciﬁc
IgG assay [27] developed on the Meso Scale Discovery platform
(Gaithersburg MD). Subjects with a ≥4-fold rise in Ga, Gb, or N-
speciﬁc antibodies were considered to be exposed to wildtype RSV,
and their immunogenicity data were excluded from that timepoint
onward; however, no subject was  excluded from day 29 analy-
ses. PCAs were assessed using an enzyme-linked immunosorbant
assay (ELISA) format where biotin-labeled palivizumab was  mixed
with serum samples and added to RSV F antigen-coated plates,
and bound palivizumab was  detected with horseradish peroxidase-
conjugated streptavidin. PCA values were reported relative to a
reference standard. Values below the lower limit of quantiﬁcation
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Table  1




RSV sF 20 g
N = 20
n (%)
RSV sF 20 g + GLA-SEa
N = 20
n  (%)
RSV sF 50 g
N = 20
n (%)
RSV sF 50 g + GLA-SEa
N = 20
n (%)
RSV sF 80 g
N = 20
n (%)
RSV sF 80 g + GLA-SEa
N = 20
n (%)
Any symptom 6 (25.0) 4 (20.0) 15 (75.0) 7 (35.0) 14 (70.0) 9 (45.0) 17 (85.0)
Fatigue or tiredness 4 (16.7) 3 (15.0) 4 (20.0) 4 (20.0) 2 (10.0) 4 (20.0) 6 (30.0)
Fever  ≥100.4 ◦F 0 1 (5.0) 0 0 0 0 0
Generalized muscle
aches
1 (4.2) 1 (5.0) 2 (10.0) 1 (5.0) 3 (15.0) 1 (5.0) 2 (10.0)
Headache 2 (8.3) 2 (10.0) 3 (15.0) 3 (15.0) 1 (5.0) 4 (20.0) 2 (10.0)
Pain  at the site of
injection
1 (4.2) 0 8 (40.0) 1 (5.0) 13 (65.0) 1 (5.0) 12 (60.0)
Redness at the site of
injection
0 0 1 (5.0) 0 1 (5.0) 0 0
Swelling at the site of
the injection
0 0 0 0 2 (10.0) 0 1 (5.0)
Tenderness or soreness
at the site of the
injection
1 (4.2) 1 (5.0) 13 (65.0) 4 (20.0) 11 (55.0) 2 (10.0) 13 (65.0)


































wLA = glucopyranosyl lipid A; RSV = respiratory syncytial virus; SE = stable emulsion
a 2.5 g of GLA in 2% SE.
LLOQ) were assigned a value of 2.28 g/mL (1/2 of the LLOQ) for
nalyses. The ELISPOT assay was performed using RSV F peptides
s previously described [28]. For results <LLOQ, a value equal to
he LLOQ (33.3 spot-forming cells [SFC] per 106 peripheral blood
ononuclear cells) was imputed. Seroresponse data are presented
s ≥3-fold rise from baseline. Based on the precision of the assays,
here was a <5% chance that a 3-fold rise from baseline would be
ue to chance.
.7. Statistical analysis
The sample size was selected to provide initial assessment
f safety and immunogenicity; cohort size did not support mul-
iple pairwise comparisons between treatment groups. Placebo
ata from 6 cohorts were grouped for presentation. There was  no
mputation of missing data. Formal statistical comparisons among
roups were not performed; for data presented with 95% con-
dence intervals (CIs), nonoverlapping CIs determined statistical
igniﬁcance. Correlation among assays was assessed with Pearson
orrelation for pairwise responses.
. Results
.1. Subjects
As planned, 144 subjects (24 per cohort) received vaccine or
lacebo as allocated (Fig. S1). Two placebo recipients withdrew
onsent; all others were followed through day 361. The median age
t enrollment was 68 (range 60–87) years, and 42% were >69 years
f age. Half (53%) were male, 89% were White race, and 34% were
ispanic/Latino ethnicity (Table S1). Pre-existing illness was com-
on: for example, hypertension 51%, lipid disorder 43%, diabetes
ellitus 18%, hypothyroidism 12%, ongoing pulmonary disease 7%,
oronary artery disease 7%.
.2. Tolerability and safety
Subjects receiving vaccines containing adjuvant were more
ikely to report solicited symptoms, most commonly pain or ten-
erness at the injection site (Table 1). All solicited symptoms were
ild-to-moderate in severity and generally of short duration; for
ain or tenderness, maximum duration was 2 days. The single fever
bserved was associated with gastroenteritis. The pattern of events
as not antigen dose-dependent.SV soluble fusion protein.
All AEs during days 1–28 were grade 1 or 2 except for a grade
3 event of viral gastroenteritis in a subject who received RSV sF
20 g, and two grade 3 events in two  subjects who  received 50 g
of RSV sF: bladder cancer detected after hematuria was  observed
on day 7, and day 1 worsening of staphylococcal abscesses on the
neck present at dosing. AEs occurred in only one subject per cohort,
except for back pain, which occurred in two subjects who  received
50 g of RSV sF. Serious AEs through day 361 are presented in
Table S2 and new onset chronic diseases in Table S3. None were
considered related to study dosing. No AE of special interest was
reported. Two  subjects developed hypothyroidism, but both had
received only RSV sF; no other potentially autoimmune events were
reported.
3.3. Immunogenicity
All subjects had pre-existing antibodies as measured in the
MN and F-speciﬁc IgG assays at baseline; however 47.2% had
baseline values <LLOQ in the PCA assay, and 63.9% did not have
measurable F-speciﬁc IFN- T cells at baseline. Day 29 immune
responses were RSV sF dose-dependent and were enhanced by
GLA-SE (Figs. 1 and 2). At all dosage levels, humoral and cellular
responses in all immunogenicity assays were signiﬁcantly higher
than those in placebo recipients (Fig. 2). At the highest dosage level,
80 g of RSV sF + GLA-SE, the mean log2 MN titer on day 29 was
10.46 (95% CI: 10.08, 10.84) compared with 8.75 (95% CI: 8.16, 9.34)
in placebo recipients. Among subjects in the highest dose group,
50% (95% CI: 27.2, 72.8), 100% (95% CI: 83.16, 100), and 100% (95%
CI: 83.16, 100) had a geometric mean fold rise from baseline (GMFR)
in MN,  F IgG, and PCA values, respectively, that was at least ≥3-fold
higher than baseline compared with 0 (95% CI: 0, 14.25) for each
assay in placebo recipients (Fig. 2). For the IFN- ELISPOT assay,
73.7% (95% CI: 48.80, 90.85) of subjects at this highest dose had
a ≥3-fold rise from baseline compared with 0 (95% CI: 0, 17.65)
placebo recipients.
Humoral assay results were signiﬁcantly correlated with one
another (Fig. 3) and, to a lesser extent, with IFN- ELISPOT results:
Pearson correlations were 0.763–0.852 for relationship between
humoral assay results and 0.231–0.281 between humoral and
ELISPOT responses. There was a trend among humoral responses
for an effect of baseline value on the magnitude of antibody rise
(data not shown), with those subjects entering the study with lev-
els below the median having a greater increase than those with
higher baseline values.
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Fig. 1. Immunogenicity of an RSV sF vaccine dosed at 20, 50, and 80 g, unadjuvanted and adjuvanted with 2.5 g of GLA in 2% SE (GLA-SE). Panel A: RSV microneutralization
titers, postdose day 29; Panel B: anti-F IgG antibodies, postdose day 29; Panel C: palivizumab competitive antibodies, postdose day 29; Panel D: RSV F-speciﬁc interferon-
ELISPOT  SFCs/106 PBMCs, postdose day 8. Bars represent 95% conﬁdence intervals. For microneutralization responses, there was overlap of 95% CIs between placebo and
RSV  sF 20 g alone and with GLA-SE only. Dotted line = lower limit of quantitation. Ab = antibody; ELISPOT = enzyme-linked immunospot; GLA = glucopyranosyl lipid A;
PBMC  = peripheral blood mononuclear cell; RSV = respiratory syncytial virus; SE = stable emulsion; sF = soluble fusion protein; SFC = spot-forming cells.
Fig. 2. Geometric mean fold rises from baseline in antibody (day 29) and interferon- ELISPOT values (day 8) after receipt of an RSV sF vaccine dosed at 20, 50, and 80 g,
unadjuvanted and adjuvanted with 2.5 g of GLA in 2% SE (GLA-SE). Panel A: RSV microneutralization antibody titers; Panel B: anti-F IgG antibodies; Panel C: palivizumab
competitive antibodies; Panel D: RSV F-speciﬁc interferon- ELISPOT responses. Bars represent 95% conﬁdence intervals (CI). No vaccine CI overlapped with that of placebo.
ELISPOT = enzyme-linked immunospot; GLA = glucopyranosyl lipid A; RSV = respiratory syncytial virus; SE = stable emulsion; sF = soluble fusion protein.
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Fig. 3. Correlation between day 29 postdose antibody responses to an RSV sF vaccine, unadjuvanted and adjuvanted with 2.5 g GLA in 2% SE. Panel A: RSV microneutralization
antibody titers vs anti-F IgG antibodies; Panel B: palivizumab competitive antibodies vs RSV microneutralization antibody titers; Panel C: palivizumab competitive antibodies














































is  anti-F IgG antibodies. P < 0.01 for Pearson correlation of all pairwise comparisons
E  = stable emulsion; sF = soluble fusion protein.
At the highest dosage level, 95.0% (95% CI: 75.13, 99.87) of
ubjects had a day 29 MN titer ≥67% of the baseline titer in the
valuable study population (compared with 29.2% [95% CI: 12.62,
1.09] in the placebo group); 100% (95% CI: 83.16, 100) achieved
 titer ≥67% of the baseline in RSV F IgG and PCA assays, without
verlap of 95% CIs with those of the placebo group. For day 8 F-
peciﬁc IFN- responses, 94.7% (95% CI: 73.97, 99.87) of subjects
n the highest dosing group had responses ≥67% of the baseline
ompared with only 30.0% (95% CI: 11.89, 54.28) of subjects who
eceived placebo. The effect of dosage level on the responses at the
opulation level can be seen in the reverse cumulative distribution
urves (Figs. 4 and S2).
By RSV F IgG assay, GMFRs in F IgG antibodies in subjects who
eceived RSV sF 80 g + GLA-SE declined slowly over time. GMFR
alues were 15.39 at day 61; 12.58 at day 91; 8.19 at day 181; 5.12
t day 271; and 5.27 at day 361. At each of these timepoints, 95%
Is of F IgG geometric mean titers did not overlap with those of the
lacebo group. The IFN- ELISPOT responses diminished by day 29
data not shown) and were not evaluated at later timepoints. Two of
4 placebo recipients and ﬁve subjects who received 80 g of RSV
F seroconverted to a nonvaccine antigen (Ga, Gb, or N) between
ays 29 and 361; no subject who received an adjuvanted vaccine
eroconverted.
. Discussion
In this ﬁrst-time-in-human study of a vaccine comprising RSV
F with and without GLA, a TLR-4 agonist, in a stable emulsion,
n acceptable safety proﬁle and signiﬁcant immunogenicity were
emonstrated. Reactogenicity was not RSV sF dose-dependent;
owever, GLA-SE increased local reactogenicity compared with the
tudy vaccines containing RSV sF alone. Solicited symptoms were
ild-to-moderate in severity and of short duration even in the
resence of adjuvant. The most common solicited symptoms were
enderness and pain at injection sites. Other local symptoms, such
s swelling or redness at injection site, were uncommon, as were
ther systemic symptoms. There was no pattern of AEs of concern.
he overall safety proﬁle of RSV sF with GLA-SE was  acceptable at
ll doses studied.
RSV sF, particularly in the presence of GLA-SE, resulted in
ubstantial and statistically signiﬁcant (vs placebo) humoral and
ellular immune responses as assessed by RSV A MN,  F IgG, PCA,
nd RSV F-speciﬁc IFN- ELISPOT assays. The clinical signiﬁcance
f the induction of high levels of antibodies that compete with
alivizumab is unknown, because the level of palivizumab anti-
ody used for the protection of infants may  not be relevant to adults,
nd antibodies that sterically hinder binding of palivizumab, but do
ot themselves bind to the palivizumab epitope, could affect assay
esults. Overall, immune responses were RSV sF dose-dependent
nd increased in the presence of adjuvant. In an ad hoc analysis of
mmunity in subjects who did and did not receive adjuvant that glucopyranosyl lipid A; r = Pearson’s correlation; RSV = respiratory syncytial virus;
used a general linear model, the ratios of results in the adjuvant
group divided by the unadjuvanted group were all signiﬁcantly >1
(data not shown, P values 0.005–0.040 for all assays). The greatest
immunogenicity was  observed at the highest dose tested—80 g of
RSV sF + 2.5 g of GLA in 2% SE. Fold rises in MN  antibody titers were
relatively low, which could be due to subjects’ high baseline titers.
We have explored the effect of adding complement to the MN assay
and found that MN titers were enhanced in the presence of guinea
pig complement, especially in samples from subjects who received
RSV sF and GLA-SE [29]. Importantly, 95% of subjects in the high
dose group achieved a MN titer ≥67% of baseline, and this popu-
lation shift can also be seen in the reverse cumulative distribution
curves. This suggests that vaccination moved those least likely to
be protected at baseline toward lower risk.
In the highest dose group, cellular immune responses measured
by IFN- ELISPOT showed a ≥3-fold rise in 74% of subjects. This
study is the ﬁrst successful demonstration of enhanced cellular
immunity induced by an RSV vaccine for older adults. We  believe a
robust T-helper type 1 vaccine response is an important contributor
to protection from disease, perhaps through clearance of virally-
infected cells [30,31]. In an ongoing study, the cellular immune
response to the vaccine is being characterized in greater detail. In
animal models, both the GLA and SE portions of the adjuvant were
important contributors to humoral and cellular immunogenicity
[22]. Data from this phase 1a study conﬁrm that inclusion of GLA-
SE in an sF-containing vaccine induces greater humoral and cellular
immune responses. The immune response did not plateau with
escalating antigen doses, suggesting that even greater immuno-
genicity might be achieved with higher doses of RSV sF. For this
reason, the follow-up phase 1b study (NCT02289820) assesses anti-
gen doses of 120 g of RSV sF as well as 3 dosage levels of GLA
(administered with 2% SE).
There are several limitations to this study. Although cohort sizes
were appropriate for a ﬁrst-in-human study, they were too small
to distinguish statistically signiﬁcant differences between dosing
groups; however, the dose–response data were useful for dose
selection. The use of a single dose level of adjuvant is a limitation
being addressed in an ongoing phase 1b study. In addition, although
subjects were permitted to enroll with stable chronic illnesses and
medication usage expected in this age group, exclusion criteria may
have skewed the population toward one that is less representa-
tive of the overall population ≥60 years of age. Broader inclusion
criteria are used in subsequent studies. Finally, although duration
of immunity at higher doses is still being explored, data from this
study suggest that annual vaccination is likely to be required. Given
that RSV and inﬂuenza illnesses occur with similar seasonality, it
would be convenient to administer an adult RSV vaccine at the same
time as an inﬂuenza vaccine (administered in the contralateral arm
to avoid inadvertent adjuvant effect on the inﬂuenza vaccine). No
interference between a subunit RSV vaccine and inﬂuenza vaccine
is expected based on previous studies of RSV vaccines and other
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Baseline Day 29
Fig. 4. Reverse cumulative distribution curves of antibody titers and IFN- spot-forming cells per 106 PBMCs before and after receipt of an RSV sF vaccine unadjuvanted
and  adjuvanted with 2.5 g of GLA in 2% SE. Panel A: RSV microneutralization titers; Panel B: RSV F-speciﬁc interferon- ELISPOT SFCs/106 PBMCs. Baseline values are






gSV  = respiratory syncytial virus; SE = stable emulsion; sF = soluble fusion protein.
ubunit vaccines; however, potential interference will be assessed
n future studies [32].In conclusion, safety and immunogenicity data from this phase
a study of an RSV sF vaccine in adults ≥60 years of age support
ontinued development of the vaccine and conﬁrm the immuno-
enic beneﬁt of including GLA-SE in the vaccine. Although GLA-SEcontributed to local reactogenicity, the safety proﬁle was accept-
able at all doses tested. The absence of a clear plateau of immune
response led to inclusion of a higher dosage level of RSV sF in sub-
sequent studies. A phase 1b study assessing escalating doses of
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